Archive | August, 2013

Hot Life Science Investor Mandate 1: Angel Group Looking to Allocate to Companies Producing Pre-Revenue Devices & Orphan Therapeutics

1 Aug

An angel group based in the Eastern US is currently deploying capital from its third fund. With around $15 million in total assets under management, they are looking for new opportunities within the life science space, but have no set timeline to make allocations. The group typically allocates between $250,000 and $2 million per company.

Currently, the angel group is most interested in the biotech therapeutics and medtech space, specifically only those that are targeting orphan indications. The group will not consider therapeutics and diagnostics that are treating any other indications due to the difficulty of the current FDA regulatory framework.

The angel group is currently looking for pre-revenue companies within the life science space. With that being said, they would consider companies in the biotech therapeutics space that have products in the preclinical stage through phase III of development, and in the medtech space the firm is looking for companies that have a product in development, or have a prototype. With that being said, the firm is looking to provide seed capital to privately held, early stage firms.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 2: PE Arm of Pension Fund Seeks Add-on Acquisitions

1 Aug

A private equity investment arm of a pension plan located in Canada, which has over $100 billion in total assets under management, is looking for new opportunities in the life science sector, and is currently targeting add-on acquisition targets for one of the firm’s portfolio companies. The pension’s equity investment size will vary depending on the size of the add-on target, however the firm is looking to acquire a strategic partner for their portfolio company as soon as possible.

The PE arm is currently looking for firms in the biotech R&D services sector. More specifically, they are seeking small, clinical-focused contract research organizations (CROs), and are most interested in firms that specialize in the areas of cardiology and endocrinology. The fund already has a good deal of exposure to clinical CRO’s that specialize in the oncology space, and thus would not be interested in investing in a company with exposure to that area.

The fund is currently only seeking firms for acquisition, and thus is only looking for firms that are interested in a buyout or recapitalization transaction. The pension is seeking firms that have around $2-5 million in EBITDA.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Life Science Investor Mandate 3: PE Group Targets Orphan Diseases, Neurological Disorders

1 Aug

A private equity group headquartered in the Western United States is looking for new opportunities in the life sciences space, and although it has no set time frame to make allocations, the firm would invest in a company within the next six months if a compelling opportunity were identified. The firm’s equity investments can range anywhere from $1-25 million.

The firm is most interested in the biotech therapeutics sector, as well as the medical technology space. In terms of companies in the medtech space, they are most interested in firms producing optical devices and active implantable devices. In the biotech therapeutics space, the firm is looking for firms developing drugs targeting neurological disorders of all kinds. They also have a particular interest in companies that are developing therapeutics targeting orphan diseases.

The firm will invest in both pre-revenue companies, as well as companies that have products that are already on the market. The group has a venture capital approach to investing in pre-revenue companies, and for those that have products on the market, it has more of a growth equity approach.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Newer Entries →